The 90-Day Advantage

On April 28, 2026, the FDA launched two proof-of-concept trials, run with AstraZeneca and Amgen, that transmit safety signals and endpoint data to reviewers in real time as a trial progresses — not months later when batch data finally clears the pipeline. The agency has set August 2026 as the point for finalizing its first pilot selections.

This eBook argues that the distinction between reading this as news and reading it as a deadline is the distinction that will separate the sponsors selected for that first cohort from everyone else. It walks through what changed in how trial data moves, what the pilot will expose about a sponsor's data infrastructure, and what a short runway can still close.

The eBook proposes a five-pillar readiness framework spanning real-time data architecture, AI-powered signal intelligence, secure and compliant AI governance, agentic workflow orchestration, and protocol digitalization through a machine-readable digital twin. It includes a six-dimension self-assessment VPs of Clinical Operations can complete in five minutes, and an anonymized case study showing a Phase 1b-to-Phase 2 timeline compressed by four months after a dosing anomaly was caught three weeks earlier than the old batch-review cycle would have allowed.